Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults

Autor: Antonella Vitale, Maria-Cristina Puzzolo, Paolo Di Bartolomeo, Martina Canichella, Maria-Stefania De Propris, Sabina Chiaretti, Piera Viero, Gimema Investigators, Massimiliano Bonifacio, Alessandra Mancino, Marco Vignetti, Alfonso Piciocchi, Anna Guarini, Monia Lunghi, Alessandro Rambaldi, Felicetto Ferrara, Francesco Fabbiano, Loredana Elia, Renato Bassan, Nicola Fracchiolla, Robin Foà
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Oncology
030204 cardiovascular system & hematology
0302 clinical medicine
hemic and lymphatic diseases
Antibodies
Bispecific
Antineoplastic Combined Chemotherapy Protocols
80 and over
Philadelphia Chromosome
dasatinib
030212 general & internal medicine
PH+ ALL
acute lymphoblastic leukemia
adult
Aged
80 and over
biology
Remission Induction
Hematopoietic Stem Cell Transplantation
hemic and immune systems
Induction Chemotherapy
General Medicine
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allografts
Dasatinib
Treatment Outcome
Ph-positive acute lymphoblastic leukemia
Female
Bispecific
Blinatumomab
Antibody
Tyrosine kinase
medicine.drug
medicine.medical_specialty
Philadelphia chromosome
Antibodies
03 medical and health sciences
Internal medicine
medicine
Humans
Survival analysis
Aged
business.industry
dasatinib-blinatumomab for ph positive acute lymphoblastic leukemia in adults
Induction chemotherapy
medicine.disease
Survival Analysis
Consolidation Chemotherapy
Settore MED/15 - MALATTIE DEL SANGUE
Mutation
biology.protein
business
Popis: Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission ...
Databáze: OpenAIRE
Externí odkaz: